Immunotech Biopharm Ltd
HKEX:6978
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Immunotech Biopharm Ltd
HKEX:6978
|
CN |
|
S
|
STX Corp
KRX:011810
|
KR |
|
Shree Cement Ltd
NSE:SHREECEM
|
IN |
|
Avance Technologies Ltd
BSE:512149
|
IN |
|
M
|
MLP Group SA
WSE:MLG
|
PL |
Immunotech Biopharm Ltd
Immunotech Biopharm Ltd. operates as an investment holding company, which through its subsidiaries engages in research and development, manufacturing and commercialization of immune cell products for treatments of cancers in the PRC. The company is headquartered in Beijing, Beijing and currently employs 515 full-time employees. The company went IPO on 2020-07-10. Its main products are EAL, CAR-T cell series and TCR-T cell series products. EAL is a multi-target cellular immunotherapy product. The company also provides cell cryopreservation services. The firm mainly conducts its businesses in the domestic market.
Immunotech Biopharm Ltd. operates as an investment holding company, which through its subsidiaries engages in research and development, manufacturing and commercialization of immune cell products for treatments of cancers in the PRC. The company is headquartered in Beijing, Beijing and currently employs 515 full-time employees. The company went IPO on 2020-07-10. Its main products are EAL, CAR-T cell series and TCR-T cell series products. EAL is a multi-target cellular immunotherapy product. The company also provides cell cryopreservation services. The firm mainly conducts its businesses in the domestic market.
